You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR alteration

Showing 1 - 25 of 1,115
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Cholangiocarcinoma, FGFR2 Fusion, FGFR2 Gene Mutation Trial in United States (TT-00420)

Recruiting
  • Cholangiocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +16 more
Jan 3, 2023

Advanced or Recurrent Solid Tumors, FGFR Gene Alterations Trial in Japan (E7090)

Recruiting
  • Advanced or Recurrent Solid Tumors
  • FGFR Gene Alterations
  • Aoba-ku, Sendai, Miyagi, Japan
  • +4 more
May 9, 2022

NSCLC (NSCLC) Trial in Worldwide (Pemigatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Los Angeles, California
  • +41 more
Jun 27, 2022

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Solid Tumours Trial in Worldwide (Debio1347 (CH5183284))

Terminated
  • Solid Tumours
  • Debio1347 (CH5183284)
  • Boston, Massachusetts
  • +7 more
Sep 8, 2020

Solid Tumor, Adult, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma Trial in Taiwan, United States (KIN-3248)

Recruiting
  • Solid Tumor, Adult
  • +2 more
  • La Jolla, California
  • +4 more
Aug 9, 2022

Advanced Solid Tumor Trial in Shanghai (Anlotinib)

Recruiting
  • Advanced Solid Tumor
  • Shanghai, Shanghai, China
  • +2 more
Apr 25, 2019

Intrahepatic Cholangiocarcinoma Trial (derazantinib)

Available
  • Intrahepatic Cholangiocarcinoma
  • (no location specified)
Jan 13, 2023

Bladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma Trial in Toronto (biological, procedure,

Recruiting
  • Bladder Carcinoma
  • +7 more
  • Atezolizumab
  • +5 more
  • Toronto, Ontario, Canada
    University Health Network Princess Margaret Cancer Center LAO
Nov 8, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Houston (drug, other, procedure)

Active, not recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Jul 21, 2022

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +23 more
  • Birmingham, Alabama
  • +166 more
Feb 2, 2023

Cholangiocarcinoma Trial in Worldwide (Pemigatinib)

Completed
  • Cholangiocarcinoma
  • Anchorage, Alaska
  • +119 more
Apr 4, 2022

Advanced Lymphoma, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Tumor Trial in Philadelphia (FGFR Inhibitor

Completed
Has Results
  • Advanced Lymphoma
  • +5 more
  • FGFR Inhibitor AZD4547
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
Jun 8, 2021

Soft Tissue Sarcoma Trial in France (drug, combination product, other)

Recruiting
  • Soft Tissue Sarcoma
  • Bordeaux, France
  • +17 more
Oct 4, 2022

Glioblastoma, Adult-type Diffuse Gliomas Trial in Worldwide (Pemigatinib)

Recruiting
  • Glioblastoma
  • Adult-type Diffuse Gliomas
  • Beverly Hills, California
  • +83 more
Jul 25, 2022

Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

Not yet recruiting
  • Cholangiocarcinoma
  • Tinengotinib 8 mg
  • +2 more
  • Santa Monica, California
  • +13 more
Jul 7, 2023

Bladder Cancer Trial in Indianapolis, Baltimore, Rockledge (Dovitinib)

Terminated
Has Results
  • Bladder Cancer
  • Indianapolis, Indiana
  • +2 more
Jul 7, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR2 Gene Amplification Trial in Canada, United States (Docetaxel, FGFR

Completed
Has Results
  • FGFR1 Gene Amplification
  • +7 more
  • Birmingham, Alabama
  • +1083 more
May 25, 2021

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

HNSCC, Head and Neck Tumors Trial in Seoul (BYL719, Poziotinib, Nintedanib)

Completed
  • HNSCC
  • Head and Neck Neoplasms
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Mar 27, 2022

Advanced Solid Tumor Trial in Worldwide (Erdafitinib)

Recruiting
  • Advanced Solid Tumor
  • Tucson, Arizona
  • +199 more
Jan 27, 2023

Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)

Recruiting
  • Solid Tumor
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Cholangiocarcinoma Metastatic Trial in China (TT-00420 (tinengotinib))

Not yet recruiting
  • Cholangiocarcinoma Metastatic
  • TT-00420 (tinengotinib)
  • Guangzhou, Guangdong, China
  • +6 more
Sep 26, 2023